One in a series
Distinguished Senior Research Scholar
Tyler Curiel, M.D., M.P.H., professor, Daisy M. Skinner President’s Chair in Cancer Immunology, Division of Hematology/Oncology, Department of Medicine; professor, Department of Microbiology, Immunology and Molecular Genetics, Joe R. & Teresa Lozano Long School of Medicine
Remarks by Dr. Henrich at the March 6 awards dinner:
Dr. Curiel is a physician-scientist with a wealth of clinical experience in phase 1 experimental therapeutics and gynecological cancers. His laboratory expertise is in human immunology with an emphasis on understanding the immunopathologic basis of human diseases, including cancer, infections and autoimmunity. He has been funded by NIH and other entities since 1987. Just last week, Dr. Curiel learned that he was funded by the NIH for the largest RO1 grant he has yet to receive, and the maximum of more than $3 million allowed by the NIH for a standard RO1. The work of the grant will help address perplexing issues facing cancer research today and is the latest achievement of Dr. Curiel’s lab that shakes up the existing paradigm regarding immunotherapy drugs and trials.
Dr. Curiel is an internationally respected immunologist who has been the leader of multiple major collaborative grants bringing together cancer researchers, cancer clinical investigators and aging experts together for major NIC, NCI and Aging awards. His contributions will continue to excel and accelerate the translation of discovery of new immunological science into new treatments for cancer and aging related disorders. We are very proud of you, Tyler.
From the nominating letter by W. Brian Reeves, M.D. FACP, FASN, Medicine, Joe R. & Teresa Lozano Long School of Medicine
Dr. Curiel is one of the most productive researchers in the Department of Medicine with a primary focus on immunology research with profound impact on cancer care and aging research. Exceptionally well-funded with national and international peer-reviewed grants and awards, his current research efforts are extremely important for the future success of our cancer center and its National Cancer Institute P30 grant renewal and quest for an NCI comprehensive cancer center designation.
He is an internationally respected immunologist whose team has made significant discoveries in autoimmunity and immune dysfunction in aging, leading to new grant funding and publications. This has made him one of the most highly cited scientists in immunology research. Dr. Curiel has been a leader of multiple major collaborative grants, bringing together cancer researchers, aging experts and cancer clinical investigators for major NIH, NCI and Aging grants and awards. His contributions will continue to excel and accelerate the translation of discovery of new immunological science into new treatments for cancer and aging-related disorders.